Effective glaucoma therapeutic agent prepared from prostaglandin composition

Abstract

The invention discloses an effective glaucoma therapeutic agent prepared from a prostaglandin composition. The glaucoma therapeutic agent is prepared by compounding prostaglandins and inhibitors, andfurther comprises glucocorticoid, an adjuvant drug capable of acting on eyes, and isotope calibration objects for tracing, wherein the glucocorticoid specifically refers to one or several of hydrocortisone, prednisone, prednisolone and medicinal salts or compound esters thereof; the adjuvant drug specifically refers to any one or a combination of several of unoprostone, tafluprost and AL-6589. Theeffective glaucoma therapeutic agent can achieve the effect of persistently and efficiently reducing the intraocular pressure to treat glaucoma, overcomes eye disorders caused by prostaglandins, obviously reduces the incidence rate of the disorders while achieving the same intraocular pressure reducing effect, particularly can promote dissolution of active ingredients, has an antibacterial effect, and provides a basis of observation for accurate treatment by displaying the targeted area and the drug flow direction by virtue of the isotope calibration objects for tracing.

Description

technical field [0001] The invention relates to the technical field, in particular to an effective glaucoma therapeutic agent obtained by combining prostaglandin substances. Background technique [0002] Glaucoma is a refractory ophthalmic disease with a risk of blindness caused by elevated intraocular pressure and damage to the internal tissues of the eyeball (retina, optic nerve, etc.) caused by various etiologies. The treatment method for glaucoma is generally to reduce intraocular pressure therapy, representative therapy includes drug therapy, laser therapy, surgical therapy and so on. [0003] Clinically commonly used antihypertensive drugs include: cholinergic drugs, cholinesterase inhibitors, adrenal beta receptor blockers, hypertonic dehydrating agents, etc., and prostaglandins are new drugs that have been studied and proven effective in lowering intraocular pressure in recent years. It lowers intraocular pressure by increasing the outflow of aqueous humor through t...

AI Technical Summary

Problems solved by technology

However, the existing drugs have certain side effects while lowering the intraocular pressure, and it is only a question of whether the side effects are large or small. In particular, long-term use of the drugs is likely to cause eye dryness and other complications

[0004] In the existing technical solutions, such as the application number 200710058349.0 published a pharmaceutical composition and its application in the preparation of drugs for the treatment of glaucoma, can overcome certain side effects, but also can not overcome the problems such as its complications, and in In the existing technical means, it is impossible to achieve the drug-guided targeting area and the flow direction of the tracer drug, and it is impossible to accurately grasp the therapeutic effect of each area, and it is only determined by the final effect, which will not be able to determine the actual effect. Therapeutic effect and targeted drugs, therefore, in the follow-up continuous treatment, targeted treatment cannot be carried out